The 30 references in paper З. Лугинова Г., А. Блохин Б., Е. Соловьева Ю., А. Сусеков В., З. Лугинова Г., А. Блохин Б., Е. Соловьева Ю., А. Сусеков В. (2013) “ОПЫТ 13-ЛЕТНЕЙ КОМБИНИРОВАННОЙ ГИПОЛИПИДЕМИЧЕСКОЙ ТЕРАПИИ СТАТИНАМИ С ФЕНОФИБРАТОМ У ПАЦИЕНТА ПОЖИЛОГО ВОЗРАСТА ОЧЕНЬ ВЫСОКОГО СЕРДЕЧНОСОСУДИСТОГО РИСКА” / spz:neicon:aterotromboz:y:2013:i:2:p:72-80

1
Catapano A., Reiner Z., De Backer G. et al. EAS/EAS Guidelines for the management of dyslipidemias. The Task Force for the management of dyslipideamias of the Europea Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS)//Atherosclerosis. 2011. P. 1–44.
(check this in PDF content)
2
European Guidelines on cardiovascular disease prevention in clinical practice (version 2012): The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR)//Eur. J. Prev. Cardiol. 2012. No 19 (4). P. 585–667. Epub. 2012 Jul.
(check this in PDF content)
3
Клинические рекомендации «Диагностика и коррекция нарушений липидного обмена с целью профилактики и лечения атеросклероза» (V пересмотр). 2012.
(check this in PDF content)
4
Chapman M. J., Ginsberg H. N., Amarenco P. et al. European Atherosclerosis Society Consensus Panel. Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management//Eur. Heart. J. 2011. No 32 (11). P. 1345–1361.
(check this in PDF content)
5
Robinson J. G. et al. Meta-analysis of the relationship between non-high-density lipoprotein cholesterol reduction and coronary heart disease risk//J. Am. Coll. Cardiol. 2009. No 53. P. 316–322.
(check this in PDF content)
6
Nitiyanant W., Sritara P., Deerochanawong C. et al. Lipid treatment assessment project II in Thailand (LTAP-II Thailand)//J. Med. Assoc. Thai. 2008. Vol. 91. No 6. Р. 836–845.
(check this in PDF content)
7
Fruchart J. C., Sacks F., Hermans M. P. et al. The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in patients with dyslipidemia//Am. J. Cardiology. 2008. No 17. 102 (10 Suppl). P. 1–34.
(check this in PDF content)
8
Sachdeva А., Cannon C. P., Deedwania P. C., Labresh K. A. et al. Lipid levels in patients hospitalized with coronary artery disease: an analysis of 136,905 hospitalizations in Get With The Guidelines//Am. Heart. J. 2009. No 157. P. 111–117.
(check this in PDF content)
9
Assmann G., Schulte H., Seedorf U. et al. Cardiovascular risk assessment in the metabolic syndrome: results from the Prospective Cardiovascular Munster (PROCAM) Study// Int. J. Obesity. 2008. No 32. P. 11–16.
(check this in PDF content)
10
Wiesbauer F., Blessberger H., Azar D., Goliasch G. et al. Familial-combined hyperlipidemiya in very young myocardial infarction survivors (<or=40 age)//Eur. Heart. J. 2009. No 30 (9). P. 1073–1079.
(check this in PDF content)
11
Franssen R. et al. Diabetes, obesity, metabolism. 2009. No 11 (2). P. 89–94.
(check this in PDF content)
12
The ACCORD Study Group. Long-term effects of intensive glucose lowering on cardiovascular outcomes//N. Engl. J. Med. 2011. No 364. P. 818–828.
(check this in PDF content)
13
Grundy S. M., Vega G. L., Yuan Z. et al. Effectiveness and tolerability of simvsatatin plus fenofibrate for combined hyperlipideamia (the SAFARI trial)// Am. J. Cardiol. 2006. No 98 (3). P. 427–428.
(check this in PDF content)
14
Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial//Lancet. 2005. No 366. P. 1849–1861.
(check this in PDF content)
15
HPS2-THRIVE Collaborative Group. HPS2-THRIVE randomized placebo controlled trial in 25,673 highrisk patients of ER niacin/laropiprant: trial design, prespecified muscle and liver outcomes, and reasons for stopping study treatment//Eur. Heart. J. 2013.
(check this in PDF content)
16
Michos E. D., Sibley C. T., Baer J. T., Blaha M. J., Blumenthal R. S. Niacin and statin combination therapy for atherosclerosis regression and prevention of cardiovascular disease events: reconciling the AIM-HIGH (Atherothrombosis Inter vention in Metabolic Syndrome With Low HDL/High Triglycerides: Impact on Global Health Outcomes) trial with previous surrogate endpoint trials//J. Am. Coll. Cardiol. 2012. No 59. P. 2058–2064.
(check this in PDF content)
17
Standards of medical care for patients in diabetes – 2012//Diabetes Care. 2012. Vol. 35. (suppl. 1).
(check this in PDF content)
18
HandelsmanY. et al. American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice//Endocr. Pract. 2011. No 17 (suppl 2).
(check this in PDF content)
19
Gæde P., Vedel P., Parving H.-H., Pedersen O. Intensified multifactorial intervention in patients with type 2 diabetes and microalbuminuria: the Steno type 2 randomised study//Lancet. 1999. No 353. P. 617–622.
(check this in PDF content)
20
Hansson L., Zanchetti A., Carruthers S. G. et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertention: principal results of the hypertension optimal treatment (HOT) randomized trial. HOT study Group//Lancet. 1998. No 351. P. 1755–1762.
(check this in PDF content)
21
Mancia G., Fagard R., Narkiewicz K. et al. 2013 ESH/ESC guidelines for the management of arterial hypertension//Eur. Heart. J. 2013.
(check this in PDF content)
22
The effect of intensive treatment of diabetes on the development and progression of longterm complications in insulin-dependent diabetes mellitus. The diabetes Control and Complications Trial Research Group//N. Engl. J. Med. 1993. No 329. P. 977–986.
(check this in PDF content)
23
Ohkubo Y., Kishikawa H., Araki E. et al. Intensive insulin therapy prevents the progression of diabetic microvaskular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study// Diabetes Res. Clin. Pract. 1995. No 28. P. 103–117.
(check this in PDF content)
24
The ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes//N. Engl. J. Med. 2008. No 358. P. 2560–2572.
(check this in PDF content)
25
Duckworth W., Abraira C., Moritz T. et al. Glucose control and vascular complications in veterans with type 2 diabetes//N. Engl. J. 2009. No 360. P. 129–139.
(check this in PDF content)
26
Дедов И. И., Шестакова М. В., Аметов А. С. и др. Консенсус совета экспертов Российской ассоциации эндокринологов (РАЭ) по инициации и интенсификации сахароснижающей терапии СД 2-го типа//Сахарный диабет. 2011. No 4. С. 6–17.
(check this in PDF content)
27
Сусеков А. В. Холестерин липопротеинов низкой плотности (ХС ЛНП) и ремнантный холестерин неЛВП – нужна ли рокировка для оценки сердечно-сосудистого риска?//Медицинский совет. 2013. No 9. C. 50–55.
(check this in PDF content)
28
Grundy S., Arai H., Barter P., Bersot T., Betteridge J., Carmena R., Cuevas A., Davidson M., Genest J., Kasaniemi A., Sadikot S., Santos R., Susekov A., Sy R., Tokgozogly L., Watts G., Zhao D. An International Atherosclerosis Society Position Paper: Global Recommendation for the Management of Dyslipideamia. Full Report. www.athero.org.
(check this in PDF content)
29
ESC Guidelines on diabetes, pre-diabetes and cardiovascular disease developed in collaboration with the EASD. The Task Force on diabetes, prediabetes and cardiovascular diseases of the European Association for the Study of Diabetes (EASD).
(check this in PDF content)
30
Martin S. S., Blaha M. J., Elshazly M. B., Brinton E. A. et al. Friedewald Estimated versus Directly Measured Low-Density Lipoprotein Cholesterol and Treatment Implications//J. Am. Coll. Cardiol. 2013.
(check this in PDF content)